Delcath Systems (NASDAQ:DCTH - Free Report) had its price target boosted by Craig Hallum from $18.00 to $21.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the stock.
A number of other equities analysts have also recently commented on the stock. Stephens reiterated a "buy" rating on shares of Delcath Systems in a research report on Friday, October 18th. Canaccord Genuity Group reiterated a "buy" rating and issued a $21.00 price objective on shares of Delcath Systems in a report on Friday, October 18th. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Delcath Systems in a report on Tuesday. Finally, StockNews.com raised Delcath Systems from a "sell" rating to a "hold" rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $22.25.
Check Out Our Latest Stock Analysis on DCTH
Delcath Systems Trading Up 4.7 %
Shares of DCTH stock traded up $0.64 during trading hours on Friday, hitting $14.31. 573,890 shares of the company's stock were exchanged, compared to its average volume of 303,529. The company has a market capitalization of $457.49 million, a PE ratio of -10.60 and a beta of 0.87. Delcath Systems has a 12-month low of $3.70 and a 12-month high of $14.47. The business's 50 day simple moving average is $11.48 and its 200-day simple moving average is $9.92.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. bought a new stake in Delcath Systems in the third quarter valued at $808,000. Virtu Financial LLC purchased a new stake in shares of Delcath Systems in the 3rd quarter worth about $289,000. Barclays PLC purchased a new stake in shares of Delcath Systems in the 3rd quarter worth about $104,000. Geode Capital Management LLC boosted its stake in shares of Delcath Systems by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 251,895 shares of the company's stock valued at $2,275,000 after purchasing an additional 7,298 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Delcath Systems during the third quarter valued at about $110,000. Hedge funds and other institutional investors own 61.12% of the company's stock.
About Delcath Systems
(
Get Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Read More
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
